EDMONTON, Alberta (April 1, 2021) – Today, GlycoNet announced the launch of its 2021-22 Call for Proposals competition for glycomics-based projects that address national health and medical needs in infectious diseases, chronic illnesses, cancer, and neurodegenerative disorders. Researchers across Canada will be able to apply for funding that leverages glycomics—the study of sugars in the biological systems—to tackle health challenges in current society.

“We are investing in projects across the country to help build a healthier Canada, especially in health areas that experience negative impacts as a result of the COVID-19 pandemic,” says Dr. Elizabeth Nanak, CEO, GlycoNet. “We strongly believe that our approach using glycomics will lead to improved therapeutics for challenging diseases, advanced technologies, and increased national capacity for disease prevention strategies and vaccines. All of these will improve patient lives and make our healthcare systems more sustainable.”

The 2021-22 Call for Proposals will open on April 1, 2021 with three funding streams— Clinical Partnerships, Translational, and Strategic Initiatives, each of which is designed to meet the needs of Canadian innovators, health organizations, and the life sciences and biotechnology industries. Proposals will be received and grants issued on a rolling basis. For details on how to apply, visit https://canadianglycomics.ca/research/call-for-proposals/.

About GlycoNet
GlycoNet is advancing research, innovation, and training in glycomics to improve the quality of life of Canadians. GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. Funded by the federal Networks of Centres of Excellence (NCE) program and a range of partners, the network includes over 170 researchers across Canada who focus on cancer, chronic diseases, infectious diseases, and neurodegenerative diseases. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training.

Contact
Ali Chou
Communications Associate
GlycoNet
ychou@glyconet.ca

780-231-5181